A breakthrough at the Research Institute of Mount Sinai Hospital may soon get many diabetics rid of the misery of taking insulin injections twice a day, for the researchers there have developed a once-a-week jab for type 2 diabetes patients.
Project leader Dr. Daniel Drucker has revealed that the new treatment called Exenatideis once a week, long-acting medications that imitates the action of GLP-1 (glucagon-like peptide), a naturally occurring hormone that is produced in the gut after eating, reports the Lancet.
Advertisement
Presently, patients are required to take to injections of currently available version of the drug known as Exenatide (Byetta).
During the study involving 300 patients, the researchers compared the results for patients self-injecting Exenatide once weekly against results from the conventional 14 injections a week.
They found that 75 per cent of patients receiving the once-weekly Exenatide treatment had their diabetes under control.
They also experienced fewer side effects and had no increased risk of hypoglycemia (decrease in blood sugars).
Source: ANI
LIN
They found that 75 per cent of patients receiving the once-weekly Exenatide treatment had their diabetes under control.
They also experienced fewer side effects and had no increased risk of hypoglycemia (decrease in blood sugars).
Source: ANI
LIN
Insulin Delivery Devices
Insulin delivery devices have evolved drastically since their invention in 1922. They are all aimed to provide insulin to the patients with minimal discomfort.
Advertisement
 Diabetes - Self-Monitoring of Blood Glucose (SMBG)Self-Monitoring Of Blood Glucose (SMBG) is one of the greatest advancements in the management of Diabetes. | Advertisement
|
Advertisement
Recommended Readings
Latest Diabetes News
Physical activity or exercise in the morning and afternoon reduces type 2 diabetes risk, whereas evening exercise has no such association.
Late sleepers and late risers may both have a higher risk of developing diabetes.
Semaglutide, the anti-diabetic drug operating by stimulating insulin secretion, might have the potential to supplant the need for mealtime insulin injections.
The gut bacteria known as Lachnospiraceae might have the ability to boost insulin sensitivity, potentially providing a protective barrier against diabetes.
Type 2 diabetes-led cardiovascular risk needs mandatory interdisciplinary, patient-centered care to reduce morbidity and mortality.
